A previous report showing that 18β-GA is the equivalent in efficacy to a TP agonist in human endothelial cells [17] led us to ask if TxAS was implicated in 18β-GA effects in NSCLC. This evidence concerns the gene TBXAS1 and non-small cell lung carcinoma.